Industry Research Reports

Home > Reports > Medical Care > Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Industry: Medical Care

Published: 2023-05-25

Pages: 123 Pages

Report ld: 1212978

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.

Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market is projected to reach US$ 56720 million in 2029, increasing from US$ 14380 million in 2022, with the CAGR of 21.4% during the period of 2023 to 2029. Demand from Breast Cancer Diagnosis and Treatment and Prostate Cancer Diagnosis and Treatment are the major drivers for the industry.

The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Companies, Type, Application and Regions Listed in the Report:
By Company
    Janssen
    Qiagen
    Advanced Cell Diagnostics
    ApoCell
    Biofluidica
    Clearbridge Biomedics
    CytoTrack
    Celsee
    Fluxion
    Gilupi
    Cynvenio
    On-chip
    YZY Bio
    BioView
    Fluidigm
    Ikonisys
    AdnaGen
    IVDiagnostics
    Miltenyi Biotec
    ScreenCell
    Silicon Biosystems

Segment by Type
    CellSearch
    Others

Segment by Application
    Breast Cancer Diagnosis and Treatment
    Prostate Cancer Diagnosis and Treatment
    Colorectal Cancer Diagnosis and Treatment
    Lung Cancer Diagnosis and Treatment
    Other Cancers Diagnosis and Treatment

By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        
    Latin America
        Mexico
        Brazil
        
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Each chapter of the report provides detailed information for readers to understand the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market further:
Chapter 1: Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029).
Chapter 2: Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3: Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4: Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Companies’ Outline, covering company’s basic information, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) introduction, etc. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11: Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12: QYResearch’s Conclusions of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market based on comprehensive survey.
Chapter 13: Methodology and Data Sources adopted by QYResearch.

 1 Market Overview of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
    1.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Overview
        1.1.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Scope
        1.1.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Status and Outlook
    1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Overview by Region 2018 VS 2022 VS 2029
    1.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2018-2029)
    1.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Region (2018-2023)
    1.5 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Forecast by Region (2024-2029)
    1.6 Key Regions, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
        1.6.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
        1.6.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
        1.6.3 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
        1.6.4 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
        1.6.5 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)

 2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Type
    2.1 Introduction
        2.1.1 CellSearch
        2.1.2 Others
    2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type: 2018 VS 2022 VS 2029
        2.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Type (2018-2023)
        2.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Type (2024-2029)
    2.3 Key Regions Market Size by Type
        2.3.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Type (2018-2029)
        2.3.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Type (2018-2029)
        2.3.3 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Type (2018-2029)
        2.3.4 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Type (2018-2029)
        2.3.5 Middle East and Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Type (2018-2029)

 3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Overview by Application
    3.1 Introduction
        3.1.1 Breast Cancer Diagnosis and Treatment
        3.1.2 Prostate Cancer Diagnosis and Treatment
        3.1.3 Colorectal Cancer Diagnosis and Treatment
        3.1.4 Lung Cancer Diagnosis and Treatment
        3.1.5 Other Cancers Diagnosis and Treatment
    3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application: 2018 VS 2022 VS 2029
        3.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Application (2018-2023)
        3.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Application (2024-2029)
    3.3 Key Regions Market Size by Application
        3.3.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Application (2018-2029)
        3.3.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Application (2018-2029)
        3.3.3 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Application (2018-2029)
        3.3.4 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Application (2018-2029)
        3.3.5 Middle East and Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Application (2018-2029)

 4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Competition Analysis by Players
    4.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Players (2018-2023)
    4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) as of 2022)
    4.3 Date of Key Players Enter into Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market
    4.4 Global Top Players Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Headquarters and Area Served
    4.5 Key Players Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Solution and Service
    4.6 Competitive Status
        4.6.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Rate
        4.6.2 Mergers & Acquisitions, Expansion Plans

 5 Company (Top Players) Profiles
    5.1 Janssen
        5.1.1 Janssen Profile
        5.1.2 Janssen Main Business
        5.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.1.4 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.1.5 Janssen Recent Developments
    5.2 Qiagen
        5.2.1 Qiagen Profile
        5.2.2 Qiagen Main Business
        5.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.2.4 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.2.5 Qiagen Recent Developments
    5.3 Advanced Cell Diagnostics
        5.3.1 Advanced Cell Diagnostics Profile
        5.3.2 Advanced Cell Diagnostics Main Business
        5.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.3.4 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.3.5 ApoCell Recent Developments
    5.4 ApoCell
        5.4.1 ApoCell Profile
        5.4.2 ApoCell Main Business
        5.4.3 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.4.4 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.4.5 ApoCell Recent Developments
    5.5 Biofluidica
        5.5.1 Biofluidica Profile
        5.5.2 Biofluidica Main Business
        5.5.3 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.5.4 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.5.5 Biofluidica Recent Developments
    5.6 Clearbridge Biomedics
        5.6.1 Clearbridge Biomedics Profile
        5.6.2 Clearbridge Biomedics Main Business
        5.6.3 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.6.4 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.6.5 Clearbridge Biomedics Recent Developments
    5.7 CytoTrack
        5.7.1 CytoTrack Profile
        5.7.2 CytoTrack Main Business
        5.7.3 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.7.4 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.7.5 CytoTrack Recent Developments
    5.8 Celsee
        5.8.1 Celsee Profile
        5.8.2 Celsee Main Business
        5.8.3 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.8.4 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.8.5 Celsee Recent Developments
    5.9 Fluxion
        5.9.1 Fluxion Profile
        5.9.2 Fluxion Main Business
        5.9.3 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.9.4 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.9.5 Fluxion Recent Developments
    5.10 Gilupi
        5.10.1 Gilupi Profile
        5.10.2 Gilupi Main Business
        5.10.3 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.10.4 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.10.5 Gilupi Recent Developments
    5.11 Cynvenio
        5.11.1 Cynvenio Profile
        5.11.2 Cynvenio Main Business
        5.11.3 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.11.4 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.11.5 Cynvenio Recent Developments
    5.12 On-chip
        5.12.1 On-chip Profile
        5.12.2 On-chip Main Business
        5.12.3 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.12.4 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.12.5 On-chip Recent Developments
    5.13 YZY Bio
        5.13.1 YZY Bio Profile
        5.13.2 YZY Bio Main Business
        5.13.3 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.13.4 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.13.5 YZY Bio Recent Developments
    5.14 BioView
        5.14.1 BioView Profile
        5.14.2 BioView Main Business
        5.14.3 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.14.4 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.14.5 BioView Recent Developments
    5.15 Fluidigm
        5.15.1 Fluidigm Profile
        5.15.2 Fluidigm Main Business
        5.15.3 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.15.4 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.15.5 Fluidigm Recent Developments
    5.16 Ikonisys
        5.16.1 Ikonisys Profile
        5.16.2 Ikonisys Main Business
        5.16.3 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.16.4 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.16.5 Ikonisys Recent Developments
    5.17 AdnaGen
        5.17.1 AdnaGen Profile
        5.17.2 AdnaGen Main Business
        5.17.3 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.17.4 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.17.5 AdnaGen Recent Developments
    5.18 IVDiagnostics
        5.18.1 IVDiagnostics Profile
        5.18.2 IVDiagnostics Main Business
        5.18.3 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.18.4 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.18.5 IVDiagnostics Recent Developments
    5.19 Miltenyi Biotec
        5.19.1 Miltenyi Biotec Profile
        5.19.2 Miltenyi Biotec Main Business
        5.19.3 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.19.4 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.19.5 Miltenyi Biotec Recent Developments
    5.20 ScreenCell
        5.20.1 ScreenCell Profile
        5.20.2 ScreenCell Main Business
        5.20.3 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.20.4 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.20.5 ScreenCell Recent Developments
    5.21 Silicon Biosystems
        5.21.1 Silicon Biosystems Profile
        5.21.2 Silicon Biosystems Main Business
        5.21.3 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
        5.21.4 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
        5.21.5 Silicon Biosystems Recent Developments

 6 North America
    6.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2029)
    6.2 U.S.
    6.3 Canada

 7 Europe
    7.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2029)
    7.2 Germany
    7.3 France
    7.4 U.K.
    7.5 Italy
    7.6 Russia
    7.7 Nordic Countries
    7.8 Rest of Europe

 8 Asia-Pacific
    8.1 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2018-2029)
    8.2 China
    8.3 Japan
    8.4 South Korea
    8.5 Southeast Asia
    8.6 India
    8.7 Australia
    8.8 Rest of Asia-Pacific

 9 Latin America
    9.1 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2029)
    9.2 Mexico
    9.3 Brazil
    9.4 Rest of Latin America

 10 Middle East & Africa
    10.1 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2029)
    10.2 Turkey
    10.3 Saudi Arabia
    10.4 UAE
    10.5 Rest of Middle East & Africa

 11 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Dynamics
    11.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends
    11.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers
    11.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
    11.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints

 12 Research Finding /Conclusion

 13 Methodology and Data Source
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer
    13.4 Author List

List of Tables
    Table 1. Global Market Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
    Table 2. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2018-2023) & (US$ Million)
    Table 3. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Share by Region (2018-2023)
    Table 4. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 5. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size Share by Region (2024-2029)
    Table 6. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
    Table 7. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2018-2023) & (US$ Million)
    Table 8. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2018-2023)
    Table 9. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 10. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2024-2029)
    Table 11. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2018-2023) & (US$ Million)
    Table 12. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2024-2029) & (US$ Million)
    Table 13. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2018-2023) & (US$ Million)
    Table 14. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2024-2029) & (US$ Million)
    Table 15. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2018-2023) & (US$ Million)
    Table 16. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2024-2029) & (US$ Million)
    Table 17. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2018-2023) & (US$ Million)
    Table 18. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2024-2029) & (US$ Million)
    Table 19. Middle East and Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2018-2023) & (US$ Million)
    Table 20. Middle East and Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2024-2029) & (US$ Million)
    Table 21. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
    Table 22. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2018-2023) & (US$ Million)
    Table 23. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2018-2023)
    Table 24. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 25. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2024-2029)
    Table 26. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2018-2023) & (US$ Million)
    Table 27. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2024-2029) & (US$ Million)
    Table 28. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2018-2023) & (US$ Million)
    Table 29. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2024-2029) & (US$ Million)
    Table 30. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2018-2023) & (US$ Million)
    Table 31. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2024-2029) & (US$ Million)
    Table 32. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2018-2023) & (US$ Million)
    Table 33. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2024-2029) & (US$ Million)
    Table 34. Middle East and Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2018-2023) & (US$ Million)
    Table 35. Middle East and Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2024-2029) & (US$ Million)
    Table 36. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) by Players (2018-2023)
    Table 37. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Players (2018-2023)
    Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) as of 2022)
    Table 39. Date of Key Players Enter into Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market
    Table 40. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players Headquarters and Area Served
    Table 41. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Solution and Service
    Table 42. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Market Concentration Ratio (CR5 and HHI)
    Table 43. Mergers & Acquisitions, Expansion Plans
    Table 44. Janssen Basic Information List
    Table 45. Janssen Description and Business Overview
    Table 46. Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 47. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Janssen (2018-2023)
    Table 48. Janssen Recent Developments
    Table 49. Qiagen Basic Information List
    Table 50. Qiagen Description and Business Overview
    Table 51. Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 52. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Qiagen (2018-2023)
    Table 53. Qiagen Recent Developments
    Table 54. Advanced Cell Diagnostics Basic Information List
    Table 55. Advanced Cell Diagnostics Description and Business Overview
    Table 56. Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 57. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Advanced Cell Diagnostics (2018-2023)
    Table 58. Advanced Cell Diagnostics Recent Developments
    Table 59. ApoCell Basic Information List
    Table 60. ApoCell Description and Business Overview
    Table 61. ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 62. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of ApoCell (2018-2023)
    Table 63. ApoCell Recent Developments
    Table 64. Biofluidica Basic Information List
    Table 65. Biofluidica Description and Business Overview
    Table 66. Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 67. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Biofluidica (2018-2023)
    Table 68. Biofluidica Recent Developments
    Table 69. Clearbridge Biomedics Basic Information List
    Table 70. Clearbridge Biomedics Description and Business Overview
    Table 71. Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 72. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Clearbridge Biomedics (2018-2023)
    Table 73. Clearbridge Biomedics Recent Developments
    Table 74. CytoTrack Basic Information List
    Table 75. CytoTrack Description and Business Overview
    Table 76. CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 77. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of CytoTrack (2018-2023)
    Table 78. CytoTrack Recent Developments
    Table 79. Celsee Basic Information List
    Table 80. Celsee Description and Business Overview
    Table 81. Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 82. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Celsee (2018-2023)
    Table 83. Celsee Recent Developments
    Table 84. Fluxion Basic Information List
    Table 85. Fluxion Description and Business Overview
    Table 86. Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 87. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Fluxion (2018-2023)
    Table 88. Fluxion Recent Developments
    Table 89. Gilupi Basic Information List
    Table 90. Gilupi Description and Business Overview
    Table 91. Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 92. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Gilupi (2018-2023)
    Table 93. Gilupi Recent Developments
    Table 94. Cynvenio Basic Information List
    Table 95. Cynvenio Description and Business Overview
    Table 96. Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 97. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Cynvenio (2018-2023)
    Table 98. Cynvenio Recent Developments
    Table 99. On-chip Basic Information List
    Table 100. On-chip Description and Business Overview
    Table 101. On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 102. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of On-chip (2018-2023)
    Table 103. On-chip Recent Developments
    Table 104. YZY Bio Basic Information List
    Table 105. YZY Bio Description and Business Overview
    Table 106. YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 107. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of YZY Bio (2018-2023)
    Table 108. YZY Bio Recent Developments
    Table 109. BioView Basic Information List
    Table 110. BioView Description and Business Overview
    Table 111. BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 112. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of BioView (2018-2023)
    Table 113. BioView Recent Developments
    Table 114. Fluidigm Basic Information List
    Table 115. Fluidigm Description and Business Overview
    Table 116. Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 117. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Fluidigm (2018-2023)
    Table 118. Fluidigm Recent Developments
    Table 119. Ikonisys Basic Information List
    Table 120. Ikonisys Description and Business Overview
    Table 121. Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 122. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Ikonisys (2018-2023)
    Table 123. Ikonisys Recent Developments
    Table 124. AdnaGen Basic Information List
    Table 125. AdnaGen Description and Business Overview
    Table 126. AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 127. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of AdnaGen (2018-2023)
    Table 128. AdnaGen Recent Developments
    Table 129. IVDiagnostics Basic Information List
    Table 130. IVDiagnostics Description and Business Overview
    Table 131. IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 132. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of IVDiagnostics (2018-2023)
    Table 133. IVDiagnostics Recent Developments
    Table 134. Miltenyi Biotec Basic Information List
    Table 135. Miltenyi Biotec Description and Business Overview
    Table 136. Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 137. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Miltenyi Biotec (2018-2023)
    Table 138. Miltenyi Biotec Recent Developments
    Table 139. ScreenCell Basic Information List
    Table 140. ScreenCell Description and Business Overview
    Table 141. ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 142. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of ScreenCell (2018-2023)
    Table 143. ScreenCell Recent Developments
    Table 144. Silicon Biosystems Basic Information List
    Table 145. Silicon Biosystems Description and Business Overview
    Table 146. Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 147. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Silicon Biosystems (2018-2023)
    Table 148. Silicon Biosystems Recent Developments
    Table 149. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2023) & (US$ Million)
    Table 150. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2024-2029) & (US$ Million)
    Table 151. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2023) & (US$ Million)
    Table 152. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2024-2029) & (US$ Million)
    Table 153. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 154. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2018-2023) & (US$ Million)
    Table 155. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2024-2029) & (US$ Million)
    Table 156. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Region (2018-2023)
    Table 157. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Region (2024-2029)
    Table 158. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 159. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2023) & (US$ Million)
    Table 160. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2024-2029) & (US$ Million)
    Table 161. Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 162. Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2023) & (US$ Million)
    Table 163. Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2024-2029) & (US$ Million)
    Table 164. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Trends
    Table 165. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers
    Table 166. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
    Table 167. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
    Table 168. Research Programs/Design for This Report
    Table 169. Key Data Information from Secondary Sources
    Table 170. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Year-over-Year 2018-2029 & (US$ Million)
    Figure 2. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (US$ Million), 2018 VS 2022 VS 2029
    Figure 3. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Regions: 2022 VS 2029
    Figure 4. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size Share by Region (2024-2029)
    Figure 5. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 6. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 7. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 8. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 9. Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 10. Product Picture of CellSearch
    Figure 11. Global CellSearch Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 12. Product Picture of Others
    Figure 13. Global Others Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 14. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Share by Type:  2022 & 2029
    Figure 15. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2018-2029)
    Figure 16. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2018-2029)
    Figure 17. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2018-2029)
    Figure 18. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2018-2029)
    Figure 19. Middle East and Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2018-2029)
    Figure 20. Breast Cancer Diagnosis and Treatment Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 21. Prostate Cancer Diagnosis and Treatment Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 22. Colorectal Cancer Diagnosis and Treatment Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 23. Lung Cancer Diagnosis and Treatment Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 24. Other Cancers Diagnosis and Treatment Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 25. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Share by Application: 2022 & 2029
    Figure 26. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2018-2029)
    Figure 27. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2018-2029)
    Figure 28. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2018-2029)
    Figure 29. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2018-2029)
    Figure 30. Middle East and Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2018-2029)
    Figure 31. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 32. Global Top 5 and Top 10 Players Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share in 2022
    Figure 33. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Country (2018-2029)
    Figure 34. U.S. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 35. Canada Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 36. Germany Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 37. France Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 38. U.K. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 39. Italy Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 40. Russia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 41. Nordic Countries Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 42. Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Region (2018-2029)
    Figure 43. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 44. Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 45. South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 46. Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 47. India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 48. Australia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 49. Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Country (2018-2029)
    Figure 50. Mexico Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 51. Brazil Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 52. Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Country (2018-2029)
    Figure 53. Turkey Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 54. Saudi Arabia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 55. UAE Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029) & (US$ Million)
    Figure 56. Bottom-up and Top-down Approaches for This Report

Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.

Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market is projected to reach US$ 56720 million in 2029, increasing from US$ 14380 million in 2022, with the CAGR of 21.4% during the period of 2023 to 2029. Demand from Breast Cancer Diagnosis and Treatment and Prostate Cancer Diagnosis and Treatment are the major drivers for the industry.

The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Companies, Type, Application and Regions Listed in the Report:
By Company
    Janssen
    Qiagen
    Advanced Cell Diagnostics
    ApoCell
    Biofluidica
    Clearbridge Biomedics
    CytoTrack
    Celsee
    Fluxion
    Gilupi
    Cynvenio
    On-chip
    YZY Bio
    BioView
    Fluidigm
    Ikonisys
    AdnaGen
    IVDiagnostics
    Miltenyi Biotec
    ScreenCell
    Silicon Biosystems

Segment by Type
    CellSearch
    Others

Segment by Application
    Breast Cancer Diagnosis and Treatment
    Prostate Cancer Diagnosis and Treatment
    Colorectal Cancer Diagnosis and Treatment
    Lung Cancer Diagnosis and Treatment
    Other Cancers Diagnosis and Treatment

By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        
    Latin America
        Mexico
        Brazil
        
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Each chapter of the report provides detailed information for readers to understand the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market further:
Chapter 1: Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029).
Chapter 2: Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3: Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4: Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Companies’ Outline, covering company’s basic information, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) introduction, etc. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11: Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12: QYResearch’s Conclusions of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market based on comprehensive survey.
Chapter 13: Methodology and Data Sources adopted by QYResearch.

Industry: Medical Care

Published: 2023-05-25

Pages: 123 Pages

Report ld: 1212978

Request Sample

Pre-Order Enquiry

CHOOSE LICENSE TYPE

Single User License

USD 3350.00

Multi Users License

USD 5025.00

Corporate Users License

USD 6700.00

/uploads/payment/payIcon/masterCard-01.svg

/uploads/payment/payIcon/american-express-01.svg

/uploads/payment/payIcon/diners-club-01.svg

/uploads/payment/payIcon/discover-4-01.svg

Add to Cart

Buy Now

A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.

Speak To Our Analyst >>

WHAT QYRESEARCH OFFER?